1
|
Gradisek P, Carrara G, Antiga L, Bottazzi B, Chieregato A, Csomos A, Fainardi E, Filekovic S, Fleming J, Hadjisavvas A, Kaps R, Kyprianou T, Latini R, Lazar I, Masson S, Mikaszewska-Sokolewicz M, Novelli D, Paci G, Xirouchaki N, Zanier E, Nattino G, Bertolini G. Prognostic Value of a Combination of Circulating Biomarkers in Critically Ill Patients with Traumatic Brain Injury: Results from the European CREACTIVE Study. J Neurotrauma 2021; 38:2667-2676. [PMID: 34235978 DOI: 10.1089/neu.2021.0066] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Individualized patient care is essential to reduce the global burden of traumatic brain injury (TBI). This pilot study focused on TBI patients admitted to intensive care units (ICUs) and aimed at identifying patterns of circulating biomarkers associated with the disability level at 6 months from injury, measured by the extended Glasgow Outcome Scale (GOS-E). The concentration of 107 biomarkers, including proteins related to inflammation, innate immunity, TBI, and central nervous system, were quantified in blood samples collected on ICU admission from 80 patients. Patients were randomly selected among those prospectively enrolled in the Collaborative Research on Acute Traumatic Brain Injury in Intensive Care Medicine in Europe (CREACTIVE) observational study. Six biomarkers were selected to be associated with indicators of primary or secondary brain injury: three glial proteins (glial cell-derived neurotrophic factor, glial fibrillary acidic protein, and S100 calcium-binding protein B) and three cytokines (stem cell factor, fibroblast growth factor [FGF] 23 and FGF19). The subjects were grouped into three clusters according to the expression of these proteins. The distribution of the 6-month GOS-E was significantly different across clusters (p < 0.001). In two clusters, the number of 6-month deaths or vegetative states was significantly lower than expected, as calculated according to a customization of the corticosteroid randomization after significant head injury (CRASH) scores (observed/expected [O/E] events = 0.00, 95% confidence interval [CI]: 0.00-0.90 and 0.00, 95% CI: 0.00-0.94). In one cluster, less-than-expected unfavorable outcomes (O/E = 0.50, 95% CI: 0.05-0.95) and more-than-expected good recoveries (O/E = 1.55, 95% CI: 1.05-2.06) were observed. The improved prognostic accuracy of the pattern of these six circulating biomarkers at ICU admission upon established clinical parameters and computed tomography results needs validation in larger, independent cohorts. Nonetheless, the results of this pilot study are promising and will prompt further research in personalized medicine for TBI patients.
Collapse
Affiliation(s)
- Primoz Gradisek
- Clinical Department of Anesthesiology and Intensive Therapy, University Medical Center Ljubljana, Slovenia
- Faculty of Medicine, University of Ljubljana, Slovenia
| | - Greta Carrara
- Laboratory of Clinical Epidemiology, Department of Public Health, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Bergamo, Italy
| | | | - Barbara Bottazzi
- Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy
| | - Arturo Chieregato
- Neurointensive Care Unit, Grande Ospedale Metropolitano Niguarda, Milan, Italy
| | - Akos Csomos
- Hungarian Army Medical Center, Budapest, Hungary
| | - Enrico Fainardi
- Neuroradiology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Italy
| | - Suada Filekovic
- Clinical Department of Anesthesiology and Intensive Therapy, University Medical Center Ljubljana, Slovenia
- Faculty of Medicine, University of Ljubljana, Slovenia
| | - Joanne Fleming
- Laboratory of Clinical Epidemiology, Department of Public Health, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Bergamo, Italy
| | | | - Rafael Kaps
- General Hospital Novo Mesto, Novo Mesto, Slovenia
| | - Theodoros Kyprianou
- University of Nicosia Medical School, Nicosia, Cyprus
- University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
| | - Roberto Latini
- Laboratory of Cardiovascular Clinical Pharmacology, Department of Cardiovascular Medicine, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - Isaac Lazar
- Department of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
| | - Serge Masson
- Laboratory of Cardiovascular Clinical Pharmacology, Department of Cardiovascular Medicine, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | | | - Deborah Novelli
- Laboratory of Cardiopulmonary Physiopathology, Department of Cardiovascular Medicine, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - Giulia Paci
- Laboratory of Clinical Epidemiology, Department of Public Health, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Bergamo, Italy
| | | | - Elisa Zanier
- Laboratory of Acute Brain Injury and Therapeutic Strategies, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - Giovanni Nattino
- Laboratory of Clinical Epidemiology, Department of Public Health, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Bergamo, Italy
| | - Guido Bertolini
- Laboratory of Clinical Epidemiology, Department of Public Health, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Bergamo, Italy
| |
Collapse
|
2
|
Finazzi S, Paci G, Antiga L, Brissy O, Carrara G, Crespi D, Csato G, Csomos A, Duek O, Facchinetti S, Fleming J, Garbero E, Gianni M, Gradisek P, Kaps R, Kyprianou T, Lazar I, Mikaszewska-Sokolewicz M, Mondini M, Nattino G, Olivieri C, Poole D, Previtali C, Radrizzani D, Rossi C, Skurzak S, Tavola M, Xirouchaki N, Bertolini G. PROSAFE: a European endeavor to improve quality of critical care medicine in seven countries. Minerva Anestesiol 2021; 86:1305-1320. [PMID: 33337119 DOI: 10.23736/s0375-9393.20.14112-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
BACKGROUND Long-lasting shared research databases are an important source of epidemiological information and can promote comparison between different healthcare services. Here we present PROSAFE, an advanced international research network in intensive care medicine, with the focus on assessing and improving the quality of care. The project involved 343 ICUs in seven countries. All patients admitted to the ICU were eligible for data collection. METHODS The PROSAFE network collected data using the same electronic case report form translated into the corresponding languages. A complex, multidimensional validation system was implemented to ensure maximum data quality. Individual and aggregate reports by country, region, and ICU type were prepared annually. A web-based data-sharing system allowed participants to autonomously perform different analyses on both own data and the entire database. RESULTS The final analysis was restricted to 262 general ICUs and 432,223 adult patients, mostly admitted to Italian units, where a research network had been active since 1991. Organization of critical care medicine in the seven countries was relatively similar, in terms of staffing, case mix and procedures, suggesting a common understanding of the role of critical care medicine. Conversely, ICU equipment differed, and patient outcomes showed wide variations among countries. CONCLUSIONS PROSAFE is a permanent, stable, open access, multilingual database for clinical benchmarking, ICU self-evaluation and research within and across countries, which offers a unique opportunity to improve the quality of critical care. Its entry into routine clinical practice on a voluntary basis is testimony to the success and viability of the endeavor.
Collapse
Affiliation(s)
- Stefano Finazzi
- GiViTI Coordinating Center, Institute for Pharmacological Research Mario Negri IRCCS, Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Ranica, Bergamo, Italy
| | - Giulia Paci
- GiViTI Coordinating Center, Institute for Pharmacological Research Mario Negri IRCCS, Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Ranica, Bergamo, Italy
| | | | - Obou Brissy
- GiViTI Coordinating Center, Institute for Pharmacological Research Mario Negri IRCCS, Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Ranica, Bergamo, Italy
| | - Greta Carrara
- GiViTI Coordinating Center, Institute for Pharmacological Research Mario Negri IRCCS, Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Ranica, Bergamo, Italy
| | - Daniele Crespi
- GiViTI Coordinating Center, Institute for Pharmacological Research Mario Negri IRCCS, Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Ranica, Bergamo, Italy
| | | | - Akos Csomos
- Hungarian Army Medical Center, Budapest, Hungary
| | - Or Duek
- Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
| | | | - Joanne Fleming
- GiViTI Coordinating Center, Institute for Pharmacological Research Mario Negri IRCCS, Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Ranica, Bergamo, Italy
| | - Elena Garbero
- GiViTI Coordinating Center, Institute for Pharmacological Research Mario Negri IRCCS, Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Ranica, Bergamo, Italy -
| | - Massimo Gianni
- Department of Anesthesiology and Intensive Care, Regional Valle d'Aosta Hospital, Aosta, Italy
| | | | - Rafael Kaps
- General Hospital Novo Mesto, Novo Mesto, Slovenia
| | | | - Isaac Lazar
- Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
| | | | - Matteo Mondini
- GiViTI Coordinating Center, Institute for Pharmacological Research Mario Negri IRCCS, Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Ranica, Bergamo, Italy
| | - Giovanni Nattino
- GiViTI Coordinating Center, Institute for Pharmacological Research Mario Negri IRCCS, Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Ranica, Bergamo, Italy.,Division of Biostatistics, The Ohio State University, Columbus, OH, USA
| | - Carlo Olivieri
- Department of Anesthesiology and Intensive Care, ASL Vercelli, Vercelli, Italy
| | - Daniele Poole
- Department of Anesthesiology and Intensive Care, San Martino Hospital, Belluno, Italy
| | - Claudio Previtali
- GiViTI Coordinating Center, Institute for Pharmacological Research Mario Negri IRCCS, Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Ranica, Bergamo, Italy
| | - Danilo Radrizzani
- Department of Anesthesiology and Intensive Care, Hospital of Legnano, Legnano, Milan, Italy
| | - Carlotta Rossi
- GiViTI Coordinating Center, Institute for Pharmacological Research Mario Negri IRCCS, Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Ranica, Bergamo, Italy
| | - Stefano Skurzak
- Department of Anesthesiology and Intensive Care, San Giovanni Battista Hospital, Turin, Italy
| | - Mario Tavola
- Department of Anesthesiology and Intensive Care, ASST Lecco, Lecco, Italy
| | | | - Guido Bertolini
- GiViTI Coordinating Center, Institute for Pharmacological Research Mario Negri IRCCS, Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Ranica, Bergamo, Italy
| | | |
Collapse
|